RecruitingPhase 2NCT06153173

Mirdametinib in Histiocytic Disorders

A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders

Sponsor

Children's Hospital Medical Center, Cincinnati

Enrollment

40 participants

Start Date

Feb 5, 2024

Study Type

INTERVENTIONAL

Conditions

Histiocytic Disorders Rosai-Dorfman Disease (RDD)Langerhans Cell Histiocytosis (LCH)Juvenile Xanthogranuloma (JXG)

Summary

The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.

Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mirdametinib for people with histiocytic disorders, juvenile xanthogranuloma (jxg), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMirdametinib

Mirdametinib is administered by mouth twice daily on a continuous schedule, with each cycle being 4 weeks. Patients are instructed to take consecutive doses separated by a minimum of 6 hours and a maximum of 14 hours.

Locations(1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06153173

Related Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

NCT01351545142 locations

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

NCT0743106011 locations

Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions

NCT0737118211 locations

International Rare Histiocytic Disorders Registry (IRHDR)

NCT0228558215 locations

Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

NCT070228341 location